Company intelligence / Profile preview

Vespina Lifesciences

Newark, Delaware, United Statespitchbook.com ↗

Ownership: Private
Development stage: Other

Overview

Vespina Lifesciences has advanced its lead small molecule candidate, MH‑001, into a Phase 1 clinical trial to evaluate safety and tolerability in healthy volunteers. The study began enrolling participants in September 2024 and remains ongoing as of mid‑2025. No efficacy data or proof-of-concept results have been reported yet.

Therapeutic areas: ImmunologyPulmonology
Modalities: Small molecule
Industry: Biotech

Drug pipeline

1 asset

MH-001

Partnerships

TVM Capital Life Science (founding investor/partner)

Beyond the preview

Go deeper on Vespina Lifesciences.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Vespina Lifesciences.

Explore the full profile